Oxford GlycoSciences plc has added a second leg to its proteomics platform with last week's deal with Glaxo Wellcome plc, which takes OGS toward the clinical development step in the value chain. In fact, this is the second deal OGS has cut to use its proteomics expertise to look for biomarkers in